Anna Laakmann

Anna Laakmann, MD JD, is a highly experienced legal professional specializing in the pharmaceutical and biotechnology sectors. Currently serving as Senior Counsel for Global Commercial Operations at Amgen, Anna provides strategic legal advice to the Oncology Business Unit, focusing on precision medicine. Prior roles include Director of Pharmaceutical Counsel at Novartis, where Anna led legal efforts for the Rare Disease and Breast Cancer franchises, and as Regulatory and Commercial Pharmaceutical Counsel at Axiom. Additionally, Anna has held positions at Aclaris Therapeutics, Greenberg Traurig, and various academic institutions, teaching law and ethics while publishing extensively on topics related to FDA regulation and biomedical innovation. Anna holds a JD from Stanford Law School, an MD from the University of Pennsylvania School of Medicine, and a BA in Biology from Williams College.